Related Experiment Video
Updated: Mar 16, 2026

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
Published on: May 21, 2018
Identification of Multiple Cryptococcal Fungicidal Drug Targets by Combined Gene Dosing and Drug Affinity Responsive
Yoon-Dong Park1, Wei Sun2, Antonio Salas1
1Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Unlabelled:
Cryptococcus neoformans is a pathogenic fungus that is responsible for up to half a million cases of meningitis globally, especially in immunocompromised individuals. Common fungistatic drugs, such as fluconazole, are less toxic for patients but have low efficacy for initial therapy of the disease. Effective therapy against the disease is provided by the fungicidal drug amphotericin B; however, due to its high toxicity and the difficulty in administering its intravenous formulation, it is imperative to find new therapies targeting the fungus. The antiparasitic drug bithionol has been recently identified as having potent fungicidal activity. In this study, we used a combined gene dosing and drug affinity responsive target stability (GD-DARTS) screen as well as protein modeling to identify a common drug binding site of bithionol within multiple NAD-dependent dehydrogenase drug targets. This combination genetic and proteomic method thus provides a powerful method for identifying novel fungicidal drug targets for further development.
Importance:
Cryptococcosis is a neglected fungal meningitis that causes approximately half a million deaths annually. The most effective antifungal agent, amphotericin B, was developed in the 1950s, and no effective medicine has been developed for this disease since that time. A key aspect of amphotericin B's effectiveness is thought to be because of its ability to kill the fungus (fungicidal activity), rather than just stop or slow its growth. The present study utilized a recently identified fungicidal agent, bithionol, to identify potential fungicidal drug targets that can be used in developing modern fungicidal agents. A combined protein and genetic analysis approach was used to identify a class of enzymes, dehydrogenases, that the fungus uses to maintain homeostasis with regard to sugar nutrients. Similarities in the drug target site were found that resulted in simultaneous inhibition and killing of the fungus by bithionol. These studies thus identify a common, multitarget site for antifungal development.
Insights
Researchers identified a common drug target site in dehydrogenases for the fungicidal drug bithionol. This discovery offers a new strategy for developing effective antifungal therapies against Cryptococcus neoformans meningitis.
Area of Science:
- Mycology
- Drug Discovery
- Biochemistry
Background:
- Cryptococcus neoformans causes nearly half a million deaths globally from meningitis, particularly in immunocompromised individuals.
- Current fungistatic drugs like fluconazole have limited efficacy, while the potent fungicidal drug amphotericin B presents toxicity and administration challenges.
- There is a critical need for novel, effective, and safer antifungal therapies targeting this neglected fungal pathogen.
Purpose of the Study:
- To identify novel fungicidal drug targets for Cryptococcus neoformans.
- To elucidate the mechanism of action of the potent fungicidal agent, bithionol.
- To explore a new multitarget approach for antifungal drug development.
Main Methods:
- Utilized a combined gene dosing and drug affinity responsive target stability (GD-DARTS) screen.
- Employed protein modeling to analyze drug-target interactions.
- Investigated the fungicidal activity of bithionol against Cryptococcus neoformans.
Main Results:
- Identified a common drug binding site for bithionol across multiple NAD-dependent dehydrogenase enzymes.
- Demonstrated that bithionol simultaneously inhibits and kills the fungus by targeting these dehydrogenases.
- Highlighted the role of dehydrogenases in fungal nutrient homeostasis.
Conclusions:
- The study successfully identified a conserved multitarget site for antifungal drug development.
- The combined genetic and proteomic approach provides a powerful platform for discovering new antifungal drug targets.
- Bithionol's mechanism offers a promising avenue for developing next-generation fungicidal therapies against cryptococcosis.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Drug Discovery: Overview

